<DOC>
	<DOCNO>NCT00108264</DOCNO>
	<brief_summary>The purpose study use dendritic cell transfected amplified RNA autologous tumor cell develop vaccine strategy treatment prostate cancer patient disseminate disease .</brief_summary>
	<brief_title>Tumor RNA Transfected Dendritic Cell Vaccines</brief_title>
	<detailed_description>The specific aim : 1 ) evaluate , phase I clinical trial , safety vaccinate patient dendritic cell transfected RNA autologous cancer cell ; 2 ) analyze T cell response induce treatment ; 3 ) improve efficacy treatment develop method increase induction CD4+T cell response .</detailed_description>
	<criteria>Patients histologically confirm diagnosis metastatic prostate cancer stag D1 D3 eligible study . They must history autoimmune disease , serious intercurrent chronic acute illness , pulmonary disease , active hepatitis , serologic evidence HIV , receive corticosteroid immunosuppressive therapy . Patients exclude study receive chemotherapy form immunotherapy 6 week prior study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Active</keyword>
	<keyword>Dendritic Cells</keyword>
</DOC>